{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:33:53Z","timestamp":1791588833942,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 DK117965-01A1"],"award-info":[{"award-number":["1R01 DK117965-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 DK117418"],"award-info":[{"award-number":["1R01 DK117418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM103447"],"award-info":[{"award-number":["P20GM103447"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jcmgh.2021.04.013","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T23:31:01Z","timestamp":1620343861000},"page":"1001-1019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis"],"prefix":"10.1016","volume":"12","author":[{"given":"David J.","family":"Matye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel R.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-0129","authenticated-orcid":false,"given":"Tiangang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2021.04.013_bib1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib2","first-page":"101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","author":"Pafili","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A\u00a0regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib7","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A\u00a0mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib10","doi-asserted-by":"crossref","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","article-title":"A\u00a0nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib11","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","author":"Harrison","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis","volume":"4","author":"Mari","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/obr.12159","article-title":"Lysosomal cholesterol accumulation: driver on the road to inflammation during atherosclerosis and non-alcoholic steatohepatitis","volume":"15","author":"Hendrikx","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf4823","article-title":"Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice","volume":"8","author":"Rao","year":"2016","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib17","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1038\/s41467-020-17363-6","article-title":"An FGF15\/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in Adults study. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fmed.2020.00060","article-title":"Attenuation of the hepatoprotective effects of ileal apical sodium dependent bile acid transporter (ASBT) inhibition in choline-deficient l-amino acid-defined (CDAA) diet-fed mice","volume":"7","author":"Rao","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1194\/jlr.M089961","article-title":"Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis","volume":"60","author":"Zhou","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib22","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.30041","article-title":"Fibroblast growth factor 15-dependent and bile acid-independent promotion of liver regeneration in mice","volume":"68","author":"Kong","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.21375","article-title":"Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice","volume":"44","author":"Choi","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib26","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/hep.27792","article-title":"The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice","volume":"62","author":"Mimche","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib27","doi-asserted-by":"crossref","first-page":"G425","DOI":"10.1152\/ajpgi.00050.2011","article-title":"Role of integrins in fibrosing liver diseases","volume":"301","author":"Patsenker","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcmgh.2016.10.002","article-title":"Targeting the enterohepatic bile acid signaling induces hepatic autophagy via a CYP7A1-AKT-mTOR axis in mice","volume":"3","author":"Wang","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib29","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","article-title":"Bile acid levels are increased in the liver of patients with steatohepatitis","volume":"20","author":"Aranha","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib33","doi-asserted-by":"crossref","first-page":"100214","DOI":"10.1016\/j.jhepr.2020.100214","article-title":"TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload","volume":"3","author":"Bidault-Jourdainne","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis","volume":"178","author":"Allen","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.01.007","article-title":"Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor","volume":"128","author":"Svegliati-Baroni","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/dbi17-0007","article-title":"Targeting FXR and FGF19 to treat metabolic diseases: lessons learned from bariatric surgery","volume":"67","author":"Bozadjieva","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease: from pathophysiology to clinical effects","volume":"11","author":"Laursen","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib38","first-page":"118","article-title":"Vertical sleeve gastrectomy confers metabolic improvements by reducing intestinal bile acids and lipid absorption in mice","author":"Ding","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib39","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2337\/db18-1305","article-title":"FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis","volume":"68","author":"DePaoli","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib40","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1007\/s11695-018-3216-x","article-title":"Increased bile acids and FGF19 after sleeve gastrectomy and Roux-en-Y gastric bypass correlate with improvement in type 2 diabetes in a randomized trial","volume":"28","author":"Nemati","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib41","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00175.2020","article-title":"Assessment of the role of FGF15 in mediating the metabolic outcomes of murine vertical sleeve gastrectomy (VSG)","author":"Myronovych","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib42","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2018.11.061","article-title":"Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption","volume":"156","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib43","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1074\/jbc.M111.305789","article-title":"Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity","volume":"287","author":"Li","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.26427","article-title":"Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha-hydroxylase\/steroid response element-binding protein 2\/microRNA-33a axis in mice","volume":"58","author":"Li","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib47","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","article-title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15","volume":"66","author":"Zhou","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/toxsci\/kfs011","article-title":"Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys","volume":"126","author":"Pai","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2337\/diacare.28.2.481","article-title":"Follow-up of nutritional and metabolic problems after bariatric surgery","volume":"28","author":"Fujioka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib50","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.nut.2009.03.012","article-title":"Prevalence of nutrient deficiencies in bariatric patients","volume":"25","author":"Toh","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib51","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib52","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1073\/pnas.0600780103","article-title":"How bile acids confer gut mucosal protection against bacteria","volume":"103","author":"Hofmann","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib53","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1128\/JVI.00476-14","article-title":"Comparison of varicella-zoster virus RNA sequences in human neurons and fibroblasts","volume":"88","author":"Baird","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2021.04.013_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X21000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X21000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:26:17Z","timestamp":1778873177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X21000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["S2352345X21000849"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2021.04.013","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2021.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}